CoroFlu / Bharat Biotech, University of Wisconsin - Madison, FluGen - LARVOL DELTA

Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge. (PubMed, Vaccine) - "Furthermore, M2SR SARS-CoV-2 generated serum HAI and mucosal antibody responses against influenza similar to an H3N2 M2SR influenza vaccine. The intranasal dual influenza/COVID M2SR SARS-CoV-2 vaccine has the potential to provide protection against both influenza and COVID."

Journal • Preclinical • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants. (PubMed, Vaccines (Basel)) - "The SARS-CoV-2 M2SR vaccine also maintained strong immune responses to influenza A with high titers of anti H3 serum IgG and hemagglutination inhibition (HAI) antibody titers corresponding to those seen from the control M2SR vector alone. With a proven safety record and robust immunological profile in humans that includes mucosal immunity, the M2SR influenza viral vector expressing key SARS-CoV-2 antigens could provide more efficient protection against influenza and SARS-CoV-2 variants."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

FluGen, UW-Madison researchers developing Covid-19 vaccine (Madison.com) - "UW-Madison researchers and the vaccine companies FluGen and Bharat Biotech are developing and testing a vaccine against COVID-19 called CoroFlu....Work on CoroFlu, including testing in laboratory animal models at UW-Madison, is expected to take three to six months. Bharat Biotech, based in Hyderabad, India, will then scale up production for safety and efficacy testing in humans....CoroFlu could be in human clinical trials by this fall....CoroFlu, like M2SR, will be delivered intranasally."

New molecule • New trial • Preclinical